Gao Shui-Ping - Collaborat Innovat Ctr Canc Med, Fudan Univ

基本信息

浏览量：29

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 65 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Phase 1b Study of First-Line Fuzuloparib Combined with Modified FOLFIRINOX Followed by Fuzuloparib Maintenance Monotherapy in Pancreatic Adenocarcinoma

Miaoyan Wei,Rujiao Liu,Yunyun Xu,Xiaobing Chen,Chao Liu,Xueli Bai,Xiaochen Zhang,Shuiping Gao,Jialin Li, Zhen Sheng, Jianpo Lian, Wenliang Wang,Jian Zhang,Si Shi,Jin Xu,Xianjun Yu

BMC Medicineno. 1 (2025): 1-2

引用0浏览0WOS引用

IMM2510, an Anti-Pd-l1/vegf Bispecific Antibody Fusion Protein, in Patients with Advanced Solid Tumors: A Phase I Dose-Escalation Study

Rujiao Liu,Xichun Hu,Zhengbo Song,Jian Zhang,Jianan Jin,Shuiping Gao,Yuping Sun, Yan Zhang,Shegan Gao,Ruinuo Jia,Deqiang Jing, Yu Xu,Zhenjiu Wang,Qiying Lu,Wenzhi Tian,Xiangdong Cheng

Journal of Clinical Oncologyno. 16_suppl (2024): e14506-e14506

引用0浏览0引用

9MW2821, a Nectin-4 Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumor: Results from a Phase 1/2a Study

Jian Zhang,Rujiao Liu,Shuiping Gao,Huijuan Yang, Jian Chen, Fang Yuan,Jiyan Liu,Hongqian Guo, Shun Zhang,XingYa Li,Xin Yao, Ming Bai,Hualei Bu, Yinyin Li, Changlu Hu,Xiumin Li,Zhen Wang, ShanBing Wang,Hanmei Lou, Zhe Feng

Journal of Clinical Oncologyno. 16_suppl (2024): 3013-3013

引用0浏览0引用

Phase I/II First-in-human Study to Evaluate the Safety and Efficacy of Tissue Factor-Adc MRG004A in Patients with Solid Tumors

Wungki Park,Jian Zhang,Farshid Dayyani,Jianzhen Shan,Rujiao Liu,Robin Guo,Eileen M. O'Reilly,Zhen Liu,Shuiping Gao,Xiaohua Wu,Alexander Starodub,Alexander I. Spira,Nashat Gabrail,Satish Shah, Yiwei Chen,Dan Liu, Chen Cheng,Xianjun Yu

JOURNAL OF CLINICAL ONCOLOGY（2024）

引用0浏览0引用

Efficacy and Safety of 9 MW2821, an Antibody-Drug Conjugate Targeting Nectin-4 Monotherapy, in Patients with Recurrent or Metastatic Cervical Cancer: A Multicenter, Open-Label, Phase I/II Study

Huijuan Yang,Jian Zhang,Rujiao Liu,Shuiping Gao,Hanmei Lou,Guiling Li,Hualei Bu,Rong Li, Shanbing Wang,Shujing Shen,Mingjun Zhang, Peipei Wang, Zhe Feng, Nan Chu

GYNECOLOGIC ONCOLOGY (2024): S22-S23

引用0浏览0引用

First-in-human Study of HMPL-295, an ERK1/2 Inhibitor, in Patients with Advanced Solid Tumors: Dose-escalation Results of Monotherapy

Xianjun Yu,Jian Zhang,Yuping Sun,Yanhong Deng, Shuangshuang Guo,Wei Hong,Si Shi,Rujiao Liu,Shuiping Gao,Qi Dang, Jianwei Zhang,Weiguo Su,Michael Shi,Songhua Fan, Bo Zhang, Beiqing Pan,Xiaoyun Jia,Jian Wang, Chen Zhong, Luguang Ma

Journal of Clinical Oncologyno. 16_suppl (2024): e15112-e15112

引用0浏览0引用

Supplementary Figure S1 from SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling

Hong-Lin Jiang,He-Fen Sun,Shui-Ping Gao,Liang-Dong Li,Sheng Huang,Xin Hu,Sheng Liu,Jiong Wu,Zhi-Ming Shao,Wei Jin

openalex（2023）

引用0浏览0引用

Phase I Study of A166, an Antibody‒drug Conjugate in Advanced HER2-expressing Solid Tumours

Jian Zhang,Rujiao Liu,Shuiping Gao,Wenhua Li,Yang Chen,Yanchun Meng,Chang Liu, Wenyue Jin,Junyan Wu,Ying Wang,Yanrong Hao,Shuli Yi,Yan Qing,Junyou Ge,Xichun Hu

npj Breast Cancer（2023）

引用8浏览0WOSNATURE引用

Supplementary Figure S2 from SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling

Hong-Lin Jiang,He-Fen Sun,Shui-Ping Gao,Liang-Dong Li,Sheng Huang,Xin Hu,Sheng Liu,Jiong Wu,Zhi-Ming Shao,Wei Jin

openalex（2023）

引用0浏览0引用

Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Tables 1 Through 5 from SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling

Hong-Lin Jiang,He-Fen Sun,Shui-Ping Gao,Liang-Dong Li,Sheng Huang,Xin Hu,Sheng Liu,Jiong Wu,Zhi-Ming Shao,Wei Jin

crossref（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn